With unmet needs remaining in type 2 diabetes, pharmaceutical companies are becoming more...
- Incretin combination therapy: a breakthrough for type 2 diabetes?
- Ebola in the DRC: vaccinating in a conflict zone
- Next chapter of Ebola preparation begins as Merck’s V920 nears approval
- ASH 2018: Celgene’s Revlimid looks set for new approvals in NHL
- Breast cancer clinical trials: top drugs under investigation
NIH to support HIV care and prevention research in the US
The National Institute of Allergy and Infectious Diseases (NIAID), a National Institutes of Health (NIH) division, has announced plans to fund HIV care and prevention research in the southern US.
Incretin combination therapy: a breakthrough for type 2 diabetes?
With unmet needs remaining in type 2 diabetes, pharmaceutical companies are becoming more experimental when developing new treatments. One trend includes combining drugs in one class to determine if they are more efficacious than one drug alone. This trend has been applied to incretins, GLP-1 and GIP, with Eli Lilly recently publishing positive results for its drug candidate LY3298176.
Ebola in the DRC: vaccinating in a conflict zone
Attempts to control the Ebola outbreak in the north-eastern Democratic Republic of Congo have been hindered by ongoing conflict in the area. While Merck’s experimental Ebola vaccine was on the ground within a week of the outbreak being declared, violence and instability in the region is testing the limits of the supply and the effectiveness on vaccination strategies.
Vect-Horus and Janssen partner for neurodegenerative disease treatment
Vect-Horus has entered a research collaboration agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals for treating neurodegenerative diseases.
Amgen partners with Magellan on patient care for difficult-to-treat diseases
Amgen has entered a partnership with Magellan Rx Management to improve care for patients suffering with chronic, difficult-to-treat diseases.
Next chapter of Ebola preparation begins as Merck’s V920 nears approval
The Ebola outbreak that began in August in the Democratic Republic of Congo (DRC) has now reached over 400 cases, becoming the second largest outbreak in history according to the World Health Organization (WHO).
AstraZeneca and Cancer Research UK open functional genomics centre
AstraZeneca has partnered with Cancer Research UK to open a functional genomics centre of excellence focused on accelerating the discovery and development of new oncology medicines.
CEPI and Imperial College London collaborate on Disease X vaccines project
The Coalition for Epidemic Preparedness Innovations (CEPI) in Norway and Imperial College London have formed an alliance to develop new vaccines against known as well as unknown pathogens, which are commonly referred to as Disease X.
ASH 2018: Celgene’s Revlimid looks set for new approvals in NHL
Data from the Phase III AUGMENT trial assessing Revlimid plus rituximab in relapsed/refractory (R/R) indolent lymphoma was presented during the second day of the 2018 American Society of Hematology (ASH) conference.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.